Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-167.38M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.89 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -36.56% |
| Return on Assets (Trailing 12 Months) | -34.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.83 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.83 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.07 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 59.07M |
| Free Float | 55.49M |
| Market Capitalization | $437.15M |
| Average Volume (Last 20 Days) | 1.18M |
| Beta (Past 60 Months) | -0.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.07% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.31% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |